RA Capital Management is an asset management and venture capital firm based in Boston that pursues evidence-based investing in healthcare, life sciences, and planetary health. The firm allocates capital across private and public markets, from seed rounds to late-stage financings, to support companies developing drugs, medical devices, diagnostics, services, and research tools. It operates an in-house research engine, TechAtlas, and maintains a healthcare incubator, Raven, to help entrepreneurs build biomedical ventures. RA Capital emphasizes data-driven decision making, co-investment with partners, and often takes board seats to guide portfolio companies through development and commercialization, aiming to improve patient outcomes while building value for management teams and investors.

Alumni Ventures is a venture capital firm based in Manchester, New Hampshire, that aims to democratize venture investing for accredited individual investors. It provides access to venture and late-stage private market opportunities through funds, syndicates, and investment clubs, enabling co-investment alongside established venture capital firms. The firm leverages a large alumni network and offers focused funds and an educational platform (AV Academy) for venture investing, as well as resources to support startup founders. It emphasizes rigorous due diligence, transparency, and diversification across sectors, geographies, and stages. Alumni Ventures supports investors seeking curated exposure to technology, education, and other sectors through customizable portfolio options and concierge deal access. By combining strategic capital with a broad community of alumni and institutional partners, it helps individuals participate in venture deals that were traditionally accessible to institutions and high-net-worth investors.

MassVentures is a Massachusetts-based venture capital firm founded in 1978 that provides seed and early-stage funding to high-growth startups. It supports ventures as they move from concept to commercialization and offers mentorship, strategic guidance, and access to industry connections to help build scalable businesses. The firm backs innovations across quantum computing, clean energy, artificial intelligence, biotechnology, advanced materials, advanced manufacturing, and robotics, and operates programs such as MV Capital, MV Accelerate, and MV Spinouts to fund companies, accelerate commercialization, and translate academic research into viable enterprises. By leveraging the Massachusetts innovation ecosystem, MassVentures aims to bolster entrepreneurs outside traditional hubs and foster sustained growth within the regional economy.

Atlas Venture is a biotechnology-focused venture capital firm based in Cambridge, Massachusetts, with more than 30 years of experience in creating and building breakthrough biotech companies. It partners with life science entrepreneurs to translate cutting-edge science into medicines, supporting portfolio companies from incubation through growth stages. The firm emphasizes seed and early-stage investing and has organized separate Life Sciences and Technology teams to pursue opportunities in both domains. Through its portfolio, Atlas Venture has helped develop medicines and launched startups, with a track record of IPOs and strategic exits.

Morningside Group is a Boston-area venture capital firm founded in 1986 as a family office for the Chan family. It makes long-term investments in companies applying novel science and technology, with expertise in life sciences, digital health, AI, materials, and technology, and a commitment to ethical business practices. The firm supports education, research, and healthcare through charitable initiatives with partners including Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and MIT Morningside Academy for Design.

OrbiMed is a global healthcare-focused investment firm founded in 1989 and headquartered in New York, with offices worldwide. It invests across the healthcare spectrum, including biopharmaceuticals, life sciences tools, diagnostics, medical devices, and digital health, pursuing opportunities through private equity, venture capital, and public equity strategies. The firm backs companies at multiple stages—from startups to mature multinationals—and provides capital across the investment lifecycle, including non-dilutive financing such as royalty-based instruments and other structured debt solutions. OrbiMed emphasizes accelerating medical innovation and improving patient outcomes by combining capital with specialized expertise and a global team, supporting the development and commercialization of new therapies, devices, and health IT systems.

General Catalyst is a venture capital firm founded in 2000 that supports companies from seed to growth stages. It invests across consumer, enterprise software, fintech, crypto, and health sectors, with a growing focus on applied artificial intelligence. The firm provides capital and strategic guidance to help entrepreneurs scale, drawing on a broad network and experienced team to nurture portfolio companies. General Catalyst maintains multiple offices, including Cambridge, Massachusetts, and San Francisco, with additional locations in North America and Europe, reflecting a global approach to backing transformative technologies and business models.

Flagship Pioneering is a Cambridge, Massachusetts based venture capital firm that conceives, creates, resources, and grows first-in-category ventures to transform human health, biology, medicine, energy, and sustainability. The firm uses science-driven entrepreneurship to envision alternative futures and drive transformational outcomes through an evolutionary methodology. It combines innovative capacity, entrepreneurial leadership, and capital management in a single enterprise that systematically builds companies in health technology, biotechnology, life sciences, and agriculture. Flagship Pioneering emphasizes its people, process, and values to create impactful companies with a focus on transformative science and technology. Its approach includes partnerships with large organizations and industry collaborators such as AWS, Pfizer, GSK, IQVIA, and Thermo Fisher Scientific to accelerate innovation, and its portfolio includes Moderna, Tessera Therapeutics, Generate Biomedicines, Inari Agriculture, Quotient Therapeutics, and Lila Sciences. It is committed to creating value by inventing and building companies addressing significant challenges in healthcare and sustainability.

Invus is a global private investment firm with a long-term, partnership-focused approach to building value across a broad range of industries. Founded in 1985, the firm aligns its incentives with owner-managers and pursues transformative growth over extended horizons, supported by evergreen capital. It provides strategic guidance and capital to companies, emphasizing patient collaboration rather than quick exits. Invus invests across sectors including consumer products and services, technology, life sciences, software, industrials, and education, leveraging a global footprint with offices in New York, Paris, London, and Hong Kong. The firm emphasizes a collaborative, long-term mindset and seeks to empower entrepreneurs to transform their industries through sustained support and strategic advice.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that focuses on science-driven startups, particularly in life sciences. It emphasizes early-stage investments in disruptive companies built on strong science and teams, and is known for advancing technologies developed in academic research and national laboratories to market. The firm operates from Chicago and Seattle and is recognized for a collaborative approach, providing strategic guidance, expertise, and a broad network to support portfolio companies. ARCH seeks to partner with entrepreneurs aiming to prevent, detect, and cure disease through innovative solutions, and builds long-term relationships with scientists and researchers to translate discoveries into commercial applications.

Founder Collective is a seed and early-stage venture capital firm focused on technology startups. It backs ventures from the initial idea through IPO, with an emphasis on founder alignment, capital efficiency, and long-term partnership. The firm follows a sector-agnostic, stage-focused approach and prioritizes teams with strong information technology components. Headquartered in New York City and Cambridge, Massachusetts, the firm operates with multiple offices and a globally active investment program. It is led by a team of general partners including Micah Rosenbloom, Amanda Herson, and David Frankel, and has backed notable startups such as SeatGeek, Uber, WHOOP, Shield AI, and Suno. The firm distinguishes itself through authentic founder-investor relationships and a commitment to backing exceptional entrepreneurs who can create enduring value.

Mission BioCapital is a life science venture capital firm that provides early-stage capital and hands-on support to founders from concept through clinical development. Its leadership team has a long history of collaboration and a track record of launching dozens of early-stage life science ventures, and the firm is known for its deep technical expertise and active, founder-friendly mentorship. With offices in San Francisco and Cambridge, Massachusetts, Mission BioCapital operates in regions rich in research, discovery, and venture activity. The firm offers programs such as the Platinum Program, which provides up to $500,000 in funding, lab space, mentorship, and access to drug discovery, legal, and financial services. It collaborates with corporate and strategic partners to accelerate development and help translate scientific discoveries into therapies, including relationships with AbbVie and Ono Venture Investment. Founded in 2009, Mission BioCapital focuses on early-stage life sciences and biotechnology companies and emphasizes collaboration, innovation, and support for founders to address unmet medical needs.

New Enterprise Associates is a United States-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. The firm focuses on technology and healthcare companies across multiple stages, from seed to growth and public offerings, and aims to support entrepreneurs with more than capital by providing domain expertise, operational guidance, and assistance with product development and market expansion. NEA works with founders to navigate technical challenges and changing economic environments, leveraging a long track record of helping portfolio companies scale. Its investment scope spans software, consumer technology, medical devices, life sciences, healthcare information technology, energy technology, and related sectors, with a global footprint that includes activity in the United States, Asia, and Brazil. Beyond financing, NEA emphasizes long-term partnerships, sharing industry insights and resources with portfolio companies, and leveraging a network of venture partners, executives, and professionals to support growth and strategic initiatives. Since its founding, the firm has supported numerous portfolio companies through IPOs and acquisitions.

Spark Capital is a venture capital firm with offices in San Francisco, Boston, and New York. Founded in 2005, it backs early-stage and growth ventures across consumer, software, fintech, media, and related sectors. The firm emphasizes a founder-centric approach, aiming to support ambitious entrepreneurs with independent thinking and a collaborative partnership, rejecting rigid playbooks. It has backed notable consumer and technology companies such as Twitter, Discord, Niantic, Oculus, Warby Parker, Tumblr, Cruise, and Anthropic, among others.

Beacon Angels is a Boston-based angel investment group that backs early-stage, fast-growing companies in New England. It provides capital and strategic support to entrepreneurs, with regular monthly meetings to review opportunities. Membership is open to accredited investors seeking portfolio growth, and the group is a member of the Angel Capital Association.

Hyperplane Venture Capital is a Boston-based early-stage technology investment firm that backs exceptional founders building machine intelligence and data-driven companies. The firm concentrates on startups leveraging artificial intelligence, machine learning, sensor technology, cloud computing, automation, robotics, and related areas, seeking solutions at the intersection of perception, communication, intelligence, and insight. It often makes early checks and emphasizes long-term partnerships to help portfolio companies scale from inception toward enduring market impact. Portfolio focus includes AI-enabled infrastructure, autonomous systems, robotics, secure collaboration, supply chain visibility, and other AI-powered workflows across diverse industries. The firm partners with founders to shape solutions and build durable, iconic businesses where AI intersects with real-world workflows and infrastructure.

Third Rock Ventures is a Boston-based venture capital firm focused on life sciences and biomedical innovation. Founded in 2007, it invests in healthcare, medicine, drugs, devices, diagnostics, therapeutics, and related information technology opportunities, often leading rounds and taking active roles to accelerate portfolio companies. The firm operates primarily in the United States, with offices in Boston and San Francisco, and seeks transformative science that can advance patient outcomes, including early-stage and high-growth opportunities.

Accomplice is a seed-led venture capital firm based in Cambridge, Massachusetts, that makes early-stage technology investments. Its focus areas include cybersecurity, esports, data analytics, SMB software, emerging hardware platforms, and marketplaces. The firm emphasizes a community-driven approach, leveraging networks and platforms such as AngelList, Spearhead, BOSS, Rev, and TUGG to source and fund founders. Originally part of Atlas Venture, the technology group was rebranded as Accomplice in 2014. Accomplice is active in New England and maintains a broader footprint across the United States, Canada, and Europe.

SOSV is a global venture capital firm focused on deep-tech investments with an emphasis on ventures addressing human and planetary health. Based in Princeton, New Jersey, it supports startups from pre-seed to growth stages through extensive founder resources and accelerator-style programs that provide access to labs, offices, engineering teams, expert networks, and mentorship to accelerate product development, testing, commercialization, and fundraising. The firm operates dedicated deep-tech facilities, including SOSV SF & NY (IndieBio) and HAX in Newark, and maintains regional activity in San Francisco, New York, Newark, and Princeton. With a portfolio spanning hundreds of companies across multiple countries, SOSV seeks co-investors to join its global network and help scale portfolio companies.

Launchpad Venture Group is a Boston-based angel investment organization focused on early-stage technology and life sciences companies. It provides financial and human capital to help entrepreneurs build successful companies, leveraging a broad network of customers, service providers, partners, and potential sources of financing. Established in 2001 and serving New England, the group has invested over $125 million in more than 150 startups, aiming to establish long-term relationships with innovative founders and offering mentorship alongside investments. It actively seeks new startup applications and is a member of the Angel Capital Association.

Connecticut Innovations is the state's venture capital arm and a leading source of capital, strategic guidance, and partnerships for innovative growth companies, primarily in Connecticut. Founded in 1989 and headquartered in New Haven, the firm invests across seed, early, and later stages in sectors including software, manufacturing, life sciences, clean tech, oncology, cybersecurity, infrastructure, big data, e-commerce, and other technology-based industries. It offers flexible financing and introductions to valuable partners to help companies scale, and manages funds dedicated to AI and quantum, climate tech, and bioscience to support technology-driven startups and growth firms. The organization emphasizes building relationships and providing expert business support alongside capital investment.

Safar Partners is a venture capital investment firm based in Cambridge, Massachusetts, founded in 2018. It funds technology companies at seed to growth stages in sectors including cleantech, advanced materials, artificial intelligence and information technology, robotics, and life sciences. The firm sources opportunities through deep relationships with leading universities such as MIT, Harvard, and the University of Rochester, and provides guidance to portfolio companies as they scale. Safar Partners operates as a registered investment adviser and emphasizes applying ESG considerations within its investment approach.

Casdin Capital is a New York-based venture capital firm founded in 2012 by Eli Casdin. The firm focuses on life sciences and healthcare, including biotechnology, oncology, digital health, agtech, and related areas, and invests in private companies across stages from early to late, seeking opportunities that leverage data analysis, genomics, and precision medicine. It emphasizes partnerships with experienced teams and maintains a long-term investment horizon, and applies its data expertise to inform investment decisions while upholding ethical considerations in the industry.

Pillar VC is an early-stage venture capital firm based in Boston, founded in 2016 by a group of CEOs who have built successful companies. It backs technically driven founders across artificial intelligence, biotechnology and deep tech from inception, partnering with teams to accelerate breakthrough technologies. The firm manages substantial capital, including around 500 million in assets and a 175 million Fund IV, and has invested in roughly 90 companies, about half with university roots. Notable portfolio companies include Wayfair, Ginkgo Bioworks, DraftKings, Abridge, ButcherBox and Flywire.

Deerfield Management is a New York–based healthcare investment firm focused on advancing health outcomes through investment, research, and philanthropy. It invests across public and private markets in biotechnology, pharmaceuticals, diagnostics, healthcare services, medical devices, and digital health, using flexible funding models and strategic partnerships to support companies at various stages and to foster innovation. The firm operates an internal research and development engine to accelerate discovery and development, and maintains a philanthropic foundation that funds education, healthcare access, and initiatives to improve health outcomes. Through collaboration with strategic partners and a commitment to data-driven insights, Deerfield Management seeks to advance healthcare technology and services while building a broader, sustainable health ecosystem.

TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines in the healthcare sector. It manages a private portfolio of investments and supports companies developing better treatment options for patients, including opportunities in private and public entities led by entrepreneurs. With teams in Palo Alto and New York City, the firm emphasizes rigorous scientific evaluation and portfolio management to accelerate breakthroughs in pharmaceutical solutions and health technology across the United States and Europe.

MPM BioImpact is a venture capital firm based in Boston that invests in biotechnology, healthcare, and life sciences companies across the entire drug development process, from early research to public markets. With over 30 years of experience, the firm backs private and public companies aiming to translate scientific breakthroughs into life-saving medicines. It emphasizes building and supporting ventures that improve patient outcomes, drawing on a team of industry experts and entrepreneur partners. Its portfolio includes Orna Therapeutics, developing circular RNA medicines, Aktis Oncology, pioneering radio-pharmaceuticals, and Reunion Neuroscience, advancing psychedelic-inspired therapies for mental health. MPM BioImpact has demonstrated a track record of backing companies that produce FDA-approved drugs, engage in M&A activity, and pursue initial public offerings, reflecting a continued commitment to advancing innovative therapies.

.406 Ventures is a Boston-based venture capital firm that focuses on early-stage investments in information technology, security and infrastructure, software, and technology-enabled business services, with a strong emphasis on cybersecurity, cloud software, digital health, data analytics, fintech, AI and big data. The firm primarily backs B2B and enterprise IT companies and often acts as lead or first institutional investor, seeking to partner with founders to scale growth. It targets companies in the Northeast United States, beginning with initial commitments typically between $2 million and $5 million and total investments between $6 million and $10 million per company, with follow-on support as the company grows. The team emphasizes hands-on involvement, leveraging deep industry experience and networks to help portfolio companies succeed, including board representation. Founded in 2005 and headquartered in Boston, the firm combines operational know-how with capital to create value for entrepreneurs and investing partners.

Longwood Fund is a Boston-based venture capital firm focused on science-based healthcare companies. Founded in 2010, it invests in novel medical solutions that arise from top-tier research, commonly affiliated with institutions such as Harvard and MIT. The firm emphasizes value-added partnerships and active involvement, with partners sometimes taking co-founding leadership roles to help accelerate portfolio companies from laboratory discovery toward patient impact.

G20 Ventures is a venture capital firm based in Cambridge and Boston, Massachusetts, that provides early traction capital to East Coast enterprise technology startups. It focuses on early-stage investments in enterprise software and related infrastructure, including virtual infrastructure and cloud-based solutions, with a preference for technology risk over market risk. The firm typically targets Series A rounds, with a sweet spot of 2 to 5 million, and reserves capital for earlier-stage deals to remain involved. It emphasizes a collaborative, community-driven approach, combining capital with storytelling and industry connections to help founders scale. G20 Ventures seeks teams with a core duo including a technologist and a business leader, a product in market, and early customer validation, and it operates within the Boston area as part of a broader Northeast ecosystem.

Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland, with additional offices in San Francisco and Cambridge. The firm focuses on investing in life sciences, diagnostics, digital health, health technology, AI and machine learning, and related technology sectors, supporting breakthrough science and technology-driven companies from early to growth stages. Its portfolio targets companies that aim to deliver meaningful advances in healthcare and technology, and the firm emphasizes building a better tomorrow through strategic capital and resources that help entrepreneurs develop and scale impactful solutions across life sciences, technology and affiliated industries.

PJC is a Boston-based venture capital firm founded in 2001 that specializes in early-stage investments across industries in North America. It partners with founders to build enduring businesses, offering guidance, capital, and access to a broad professional network to support growth through various market cycles. With a relationship-focused approach grounded in industry and financial expertise, PJC seeks to empower portfolio companies by connecting them with resources and strategic insight. The firm has invested in more than 100 companies across North America, including notable early stage companies such as Expensify, Nest, BlockFi, GetWell Network, and Nexamp. PJC emphasizes collaborative partnerships rather than merely funding, aiming to be a reliable, long-term resource for entrepreneurs as they scale.

Boston Seed Capital is a venture capital firm based in the Boston area, with a Wellesley Hills, Massachusetts office, that provides seed- and early-stage funding to internet-enabled startups across the United States. It focuses on consumer goods, business services, and technology, including information technology, SaaS, cybersecurity, e-commerce, big data, marketplaces, artificial intelligence and machine learning, and esports. The firm adopts a hands-on, founder-focused approach, collaborating with entrepreneurs from concept through scale, drawing on experience in supporting both consumer and business-to-business software ventures. Founded in 2010, it aims to help early-stage companies grow in a competitive technology landscape.

CRV is an early-stage venture capital firm founded in 1970 and headquartered in Palo Alto, California, with offices in Cambridge, Massachusetts and Menlo Park, California. The firm pursues seed to Series B investments in technology, consumer products and services, and healthcare across North America, taking a value-added, hands-on approach to help portfolio companies grow from inception to market leadership. CRV emphasizes deep collaboration with founders, guiding strategy, execution, and intellectual property protection to build category-leading companies in high-growth technology, media, and related sectors.

Newpath Partners is a Boston, Massachusetts-based venture capital firm specializing in life sciences and healthcare. The firm makes multi-stage investments in life sciences and healthcare companies, providing capital and strategic support to accelerate growth, improve patient outcomes, and enhance operational efficiency. It emphasizes forming partnerships based on trust and shared vision with portfolio companies, and aims to support scientific innovation through active engagement and strategic guidance.

Samsara BioCapital is a biotech-focused venture capital and investment advisory firm based in Palo Alto, California, founded in 2016. The firm seeks to invest in biotechnology and healthcare companies across the United States, aiming to advance transformative therapeutics through scientific collaboration and strategic partnerships. It emphasizes assembling multidisciplinary teams of scientists, physicians, drug developers, and business leaders to accelerate therapeutic breakthroughs and create innovative medicines. The firm also operates as a registered investment adviser.

Tiger Global Management is an investment firm established in 2001 by Charles (Chase) Coleman that invests in both public and private markets worldwide. The firm emphasizes technology-enabled sectors and backs companies across the growth spectrum, employing public equity strategies (including long/short and growth) and private investments from early to late stages. Its global activity spans the United States and regions such as China, India, Latin America, and Eastern Europe, reflecting a focus on high-quality, innovative companies in technology, internet, consumer, and financial services sectors.

Khosla Ventures is a California-based venture capital firm founded in 2004 that provides capital and strategic guidance to technology startups across stages. It invests in companies across sectors such as artificial intelligence, healthcare, climate tech, digital health, sustainability, and consumer technology, with emphasis on bold, innovative business models and science-driven approaches. The firm manages multiple funds and takes an active, long-term partnership stance, offering operational support and strategic advice to help build durable companies. Based in Menlo Park, California, Khosla Ventures seeks to back entrepreneurs solving complex problems in AI, energy, biotech, software, and related fields, often funding early-stage ventures as well as opportunities at later stages.

EcoR1 Capital is a San Francisco-based investment firm focused on the biotechnology sector. As a venture capital investor and registered investment adviser, it partners with entrepreneurs developing novel medicines and life-saving therapeutics, supporting discovery and development through long-term collaborations. The firm emphasizes a molecular understanding of biology and chemistry to identify promising opportunities with potential patient impact, investing across early-stage and later-stage biotech companies. It backs innovative ventures addressing unmet medical needs and aims to accelerate translational research to bring transformative therapeutics to patients.

One Way Ventures is a Boston-based venture capital firm that specializes in seed-stage technology investments, with a focus on immigrant founders aiming to build global companies. Founded in 2017, the firm backs early-stage startups across the United States and Canada, primarily in software and fintech, and seeks to support ventures with the ambition to scale internationally from North America. The firm provides capital and guidance to help immigrant-led startups grow into globally oriented technology companies.

Catalyst Health Ventures is a Boston-based venture capital firm founded in 2008 that invests in healthcare and life sciences, including medical devices, diagnostics, drug delivery, digital health, and related technologies. The firm focuses on early-stage opportunities and takes a hands-on, collaborative approach to working with management and syndicate partners to build companies. Its investment thesis centers on technologies with strong engineering foundations designed to address unmet clinical needs while lowering costs and improving patient outcomes. Target areas include oncology, cardiovascular disease, obesity, and women’s health, with emphasis on devices, diagnostics, instrumentation, and consumer health solutions. CHV supports portfolio companies through strategic guidance and active participation in follow-on rounds to help realize the potential of transformative MedTech and life sciences ventures in the United States.

Prelude Ventures is a San Francisco-based venture capital firm that invests in and supports early-stage startups with solutions to mitigate climate change. The firm focuses on a broad range of sectors, including Built Environment, Carbon Management, Compute, Food & Agriculture, Energy, Manufacturing & Industrials, and Mobility. Founded in 2013, Prelude Ventures seeks to accelerate climate-focused innovation by providing capital and strategic guidance to portfolio companies.

Boxer Capital is a biotechnology investment firm that serves as the corporate venture capital arm of Tavistock Group. Based in the United States, the firm invests in public and private biotechnology and life sciences companies across the drug development lifecycle, from early discovery to commercial stage, with a focus on precision medicine and transformative medical advancements. Boxer Capital combines fundamental research with a multidisciplinary analysis of scientific, clinical, regulatory, and commercial factors to translate innovation into opportunity. It pursues opportunities across the full drug lifecycle and provides financial capital and strategic guidance to portfolio companies. The firm notes partnerships with companies such as Mirati Therapeutics and Pandion Therapeutics as examples of its collaborative approach.

Deep Track Capital is a Greenwich, Connecticut-based venture capital firm focused on the biotechnology and life sciences sectors. It invests in public and pre-IPO biotechnology companies and emphasizes partnering with management teams, offering time, expertise, and a broad network in addition to capital. The firm aims to lead transactions, form large syndicates, and participate in rounds led by other qualified investors, providing strategic guidance and resources to portfolio companies.

Borealis Ventures is a venture capital firm founded in 2002 and based in Hanover, New Hampshire, with an additional office in Portsmouth. It invests in early-stage and some growth-stage companies across life sciences, healthcare, digital health, information technology, application software, internet and mobile services, and design and engineering software, including technology commercialization from universities such as Dartmouth College. The firm typically writes initial checks in the low hundreds of thousands to a few million dollars and aims to participate in follow-on rounds; it often serves as lead investor but also co-invests with other firms or entrepreneurs. Borealis pursues national opportunities with a focus on the New England region, especially Northern New England and the Boston area, and seeks to take board seats in its portfolio companies. The firm supports companies from seed through series A and beyond, including spinouts, and emphasizes connecting the right people and resources to foster growth in its sectors.

Gaingels is a global venture investment syndicate focused on supporting LGBTQ-founded and led companies and advancing inclusive leadership across stages from early to growth. Founded in 2014 and based in New York, it maintains a portfolio of 130+ companies and about $70 million deployed, and it co-invests with other venture capital partners. Beyond capital, Gaingels assists portfolio firms in recruiting diverse talent for C-suite and board roles and fosters a worldwide community of investors, operators, and entrepreneurs dedicated to positive social change through business.

E14 Fund is a Cambridge, Massachusetts-based venture capital firm that concentrates on seed and early-stage investments in deep technology companies, with a particular focus on startups originating from MIT. It supports portfolio companies from pre-seed to Series A, helping translate academic research into commercial products and scale technologies for real-world impact. Leveraging a broad network of advisors, industry experts, and entrepreneurs, it assists portfolio firms with strategy, fundraising, and market development. The firm backs ventures across sectors such as artificial intelligence, robotics, biotechnology, smart cities, and manufacturing, and aims to build inclusive communities by partnering with diverse founders. E14 Fund positions itself as an early partner that connects founders with resources and opportunities within its ecosystem.

Arkin Capital is an Israeli investment firm based in Herzliya that operates a multi-asset platform spanning venture capital, private equity, and hedge funds. With an AUM of over $2 billion, it pursues opportunities across life sciences, biotechnology, digital health, cybersecurity, fintech, and real estate, deploying capital through four main arms: Arkin Health, Arkin Equity, Arkin Tech, and Arkin Real Estate. The firm has a global reach, investing in Israel, North America, and Europe, and has backed more than 100 companies with multiple exits, reflecting a hands-on approach to supporting entrepreneurs and growth-stage companies worldwide.

Ascent Venture Partners is a Boston-based venture capital firm that specializes in early-stage investments in enterprise technology. The firm concentrates on enterprise IT, business software and services, information technology, SaaS, cybersecurity, and related sectors, leveraging decades of B2B experience and a broad network to support portfolio companies toward market leadership and value creation. With a collaborative approach, it backs select early-stage companies with strong potential and helps them grow from concept to scale.

Flare Capital Partners is a Boston-based venture capital firm that concentrates on healthcare technology, investing in early-stage and growth companies across the United States. The firm backs healthtech opportunities spanning software, data analytics, AI-enabled platforms, diagnostics, medical devices, and digital health, with a focus on transformational technologies that support value-based care. It emphasizes partnering with founders to accelerate adoption and maximize impact, leveraging a strategic network that includes an AI Advisory Council and the Flare Scholars Program to develop future healthcare leadership. With an emphasis on leveraging data and technology to improve efficiency and outcomes, Flare Capital Partners seeks to back companies at various stages to build durable, scalable healthcare solutions.